ATE201822T1 - Verwendung von makroliden zur behandlung von zerebraler ischaemie - Google Patents

Verwendung von makroliden zur behandlung von zerebraler ischaemie

Info

Publication number
ATE201822T1
ATE201822T1 AT94903064T AT94903064T ATE201822T1 AT E201822 T1 ATE201822 T1 AT E201822T1 AT 94903064 T AT94903064 T AT 94903064T AT 94903064 T AT94903064 T AT 94903064T AT E201822 T1 ATE201822 T1 AT E201822T1
Authority
AT
Austria
Prior art keywords
pct
cerebral
hemorrhage
sec
date
Prior art date
Application number
AT94903064T
Other languages
English (en)
Inventor
John S Kelly
Steven P Butcher
John Sharkey
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE201822T1 publication Critical patent/ATE201822T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT94903064T 1992-12-29 1993-12-24 Verwendung von makroliden zur behandlung von zerebraler ischaemie ATE201822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929227055A GB9227055D0 (en) 1992-12-29 1992-12-29 New use
PCT/JP1993/001886 WO1994014443A1 (en) 1992-12-29 1993-12-24 Use of macrolides for the treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
ATE201822T1 true ATE201822T1 (de) 2001-06-15

Family

ID=10727284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903064T ATE201822T1 (de) 1992-12-29 1993-12-24 Verwendung von makroliden zur behandlung von zerebraler ischaemie

Country Status (16)

Country Link
US (1) US5648351A (de)
EP (1) EP0676961B1 (de)
JP (1) JP3038920B2 (de)
KR (1) KR100299856B1 (de)
CN (1) CN1039622C (de)
AT (1) ATE201822T1 (de)
AU (1) AU687025B2 (de)
CA (1) CA2152803A1 (de)
DE (1) DE69330312T2 (de)
DK (1) DK0676961T3 (de)
ES (1) ES2157248T3 (de)
GB (1) GB9227055D0 (de)
GR (1) GR3036008T3 (de)
PT (1) PT676961E (de)
TW (1) TW291438B (de)
WO (1) WO1994014443A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
EP1223969A2 (de) * 1999-10-04 2002-07-24 Fujisawa Pharmaceutical Co., Ltd. Kombinierte verwendung von plasminogenaktivator und interleukin-2-inhibitoren zur neuroprotektion
US20040147433A1 (en) * 2001-06-14 2004-07-29 Marcus Keep Neuroimmunophilins for selective neuronal radioprotection
JP2004323414A (ja) * 2003-04-24 2004-11-18 Japan Science & Technology Agency １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity

Also Published As

Publication number Publication date
DE69330312T2 (de) 2001-10-11
EP0676961B1 (de) 2001-06-06
GR3036008T3 (en) 2001-09-28
HK1012229A1 (en) 1999-07-30
KR100299856B1 (ko) 2001-11-22
ES2157248T3 (es) 2001-08-16
AU687025B2 (en) 1998-02-19
WO1994014443A1 (en) 1994-07-07
CN1039622C (zh) 1998-09-02
US5648351A (en) 1997-07-15
JP3038920B2 (ja) 2000-05-08
DK0676961T3 (da) 2001-09-10
CN1103580A (zh) 1995-06-14
TW291438B (de) 1996-11-21
EP0676961A1 (de) 1995-10-18
GB9227055D0 (en) 1993-02-24
PT676961E (pt) 2001-10-30
JPH08505136A (ja) 1996-06-04
AU5716094A (en) 1994-07-19
CA2152803A1 (en) 1994-07-07
KR960700055A (ko) 1996-01-19
DE69330312D1 (de) 2001-07-12

Similar Documents

Publication Publication Date Title
RU94037968A (ru) Трициклические пирролпроизводные
DE60226881D1 (de) High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
RU94037964A (ru) Производные 1-амино-этилиндола
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
DE69213451D1 (de) Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE183389T1 (de) Triphenylethylene zur vorbeugung und behandlung von osteoporose
DE69231644D1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
BR9407812A (pt) Compostos uso e processo de preparação dos mesmos composições farmacêuticas uso das mesmas e processo de tratamento de ataques distúrbios neurológicos e/ou condições nas quais há dano neurológico nos animais incluindo seres humanos
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69330312D1 (de) Verwendung von makroliden zur behandlung von zerebraler ischaemie
DE69326395D1 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
DE69823851D1 (de) Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
DE69309297D1 (de) Neuroprotektive 3,4-dihydro-2(1h)-chinolone
DE69418689D1 (de) Nitrone verwendbar zum abfangen von freien radikalen
DE69400702D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69724944D1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
BR0212151A (pt) Uso de compostos para tratar condições resultantes de dano ao nervo corneano após cirurgias de lasik e outras oculares ou traumas
DE69718925D1 (de) Verfahren zur herstellung von n-[2-(dimethylamino)ethyl]akridin-4-carbonsäureamide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee